Saunders brings decades of healthcare leadership experience, and plans to propel Korea's #1 medical aesthetics company into a global industry leader

Saunders will serve as Hugel's Executive Board Chair starting June 29, 2022

The appointment of Saunders is an example of CBC Group continuing to empower its portfolio ecosystem with introduction of seasoned executives and operators

SINGAPORE , May 20, 2022 /PRNewswire/ -- Hugel, Inc. ("Hugel", 145020.KQ), Korea's #1 leader in the botulinum toxin and hyaluronic acid fillers space, announced the appointment of Brent Saunders to its Board of Directors, effective immediately in advance of his election as Executive Chair on June 29, 2022 . The news comes on the heels of the close of the Hugel Inc. transaction by a consortium led by CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm.

Mr. Saunders brings Hugel over 25 years of expertise in the pharmaceutical and medical aesthetics industries and has facilitated over $300 billion in deals across the healthcare and life sciences sectors over the course of his career. Mr. Saunders previously served as Chairman, President, and CEO of Allergan Aesthetics until its 2020 acquisition by AbbVie in a transaction valued at approximately $63 billion . Allergan Aesthetics is the maker of Botox, the world's top-selling botulinum toxin brand, as well as the maker of leading dermal filler Judvederm. Earlier in his career, Mr. Saunders was President of Schering-Plough Corporation's Global Consumer Healthcare division, where he facilitated the company's acquisition of Organon Biosciences and the merger between Schering-Plough and Merck. Mr. Saunders also served as President and CEO of Forest Laboratories from 2013 to 2014, and Chairman and CEO of Bausch + Lomb Incorporated from 2010 to 2013. He currently serves as CEO of Vesper Healthcare Acquisition Corp.

Brent Saunders commented, "I am excited to join the world- class team at Hugel and CBC to continue building a global leader in medical aesthetics. With their commitment to operational excellence, customer service and R&D, our future is very bright."

CBC is proud to bring on a leader that shares the firm's vision to widen access to healthcare services by improving efficiency to fulfil unmet medical needs around the world. "As Asia's largest healthcare-focused investment firm, CBC is a steadfast investor-operator and serial entrepreneur, committed to connect our portfolios with top industry veterans for accelerating sustainable growth," said Fu Wei, CEO of CBC. "For decades, Brent has been one of the industry's most respected visionaries, and he has a stellar track record of taking life sciences companies to the next level. His deep understanding of the medical aesthetics industry will further accelerate Hugel's expansion beyond the Asian markets."

Son Ji -hoon, CEO of Hugel, said, "Brent Saunders is an unparalleled leader in the global medical aesthetics industry, and he achieved remarkable results in his previous roles, including at the helm of Allergan. With his expertise and global experience, we plan to become a leading company in the global medical aesthetics industry, supported by our new investors and Board of Directors. I look forward to this new phase in our development, and to providing more medical aesthetics solutions to consumers and practitioners around the world."

Hugel obtained its toxin license in China in late 2020, and rapidly gained 10% market share over its first year since launching in the country. Hugel also obtained marketing approval recommendation from the European HMA in January 2022 , in addition to country level approvals from nine European countries including UK, France , Germany , Italy , Austria , Portugal , Ireland , Netherlands , and Romania . It is in the final stage of US FDA approval, which it could secure by mid-2023, opening a tremendous opportunity in the world's largest medical aesthetics market.

CBC empowers sustainable, efficient growth of its portfolio companies throughout their lifecycles with a range of strategies including buyout, venture capital, private credit, and infrastructure solutions. Recent major milestones among its portfolio companies include the successful $67 million Series A financing of Boston -based Ensem Therapeutics, a biotechnology company focused on high-value and difficult-to-drug oncology targets, as well as a $140 million financing round for RVAC Medicines, which will support the launch of a new R&D center and manufacturing sites in Singapore to develop novel mRNA vaccines.

CBC Group, Asia's largest healthcare-dedicated investment firm, is committed to creating value and integrating global resources. Partnering with the world's top entrepreneurs and scientists, its unique investor-operator approach has empowered global leading healthcare companies to widen access to affordable medical care, catalyze innovations, and improve efficiency in fulfilling unmet medical needs worldwide. Founded in 2014, CBC has a leading team of investment, industry and portfolio management professionals headquartered in Singapore with offices in Shanghai , Beijing , Hong Kong and New York , and presences in Boston , San Diego , San Francisco , and Tokyo . CBC focuses on platform-building, buyout, credit and growth-focused opportunities across multiple core areas within the healthcare sector, including pharmaceutical and biotech, medical technology and healthcare services. For more information, please visit www.cbridgecap.com.

View original content:https://www.prnewswire.com/news-releases/cbc-welcomes-former-allergan-ceo-brent-saunders-to-join-hugel-board-as-executive-chair-301551867.html

Shares of the artificial intelligence lender Upstart Holdings (NASDAQ: UPST) traded more than 16% lower as of 11:14 a.m. ET today after it received yet another downgrade from Wall Street. Wedbush analyst David Chiaverini maintained his underperform rating on Upstart but lowered his price target from $20 to $15 per share. The lower price target comes just a week after Chiaverini lowered his price target on Upstart from $35 to $20.

An earnings recession is not the biggest threat facing the stock market right now. To show that an earnings recession doesn’t necessarily doom the stock market, consider the S&P 500’s (SPX) quarterly return when its earnings-per-share (EPS) is falling. On average over the past century, according to an analysis conducted by Ned Davis Research, the S&P 500 has performed better when its EPS were lower than a year previously — not higher.

When Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett buys or sells shares of a company, Wall Street and investors tend to pay close attention. Since becoming CEO in 1965, he's overseen the creation of more than $680 billion in shareholder value and delivered an average annual return of 20.1% for Berkshire's Class A (BRK.A) shareholders (himself included).

Shares of Nvidia (NASDAQ: NVDA) continued to tumble on Friday, falling as much as 8%. Wells Fargo analyst Aaron Rakers lowered his price target on Nvidia to $250, down from $370, while maintaining his overweight (buy) rating on the stock, according to The Fly.

Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.

Cathie Wood is a long-time Tesla bull, but the stock isn't the largest holding in Wood's ARK Innovation ETF anymore.

In this article, we discuss 6 stocks that Warren Buffett is selling in 2022. If you want to see more stocks that the billionaire sold, click Warren Buffett is Selling These 3 Stocks in 2022. Warren Buffett, the chief of Berkshire Hathaway, is perhaps the most renowned financier in the investment world, with decades of […]

The Dow Jones reversed higher while the S&P 500 battled out of bear market territory. Tesla stock dived amid reports about CEO Elon Musk.

Shares of the e-commerce platform company Shopify (NYSE: SHOP) were plunging today just one day after its share price soared by double digits. Today's drop was caused by ongoing fears about high inflation and upcoming Federal Reserve interest rate hikes. As a result, the tech-heavy Nasdaq Composite had slid 2.5% and Shopify's stock had tumbled 10.8% as of 2:44 p.m. ET.

These companies produce the only thing that matters.

Yahoo Finance Live anchors discuss second-quarter earnings for Deere.

In early trading Friday, stock markets attempted to make a comeback and at least end a losing week on a winning note. As of 12:25 p.m. ET, shares of Rivian Automotive (NASDAQ: RIVN) are off 4.9%, Nikola (NASDAQ: NKLA) stock is down 5.8%, and Lucid Group (NASDAQ: LCID) -- the beneficiary of positive news as recently as yesterday -- is giving back most of its gains, and leading the sector 6.8% lower today.

In early trading Friday, stock markets attempted to make a comeback and end a down week on an up note. As The Fly reports, Truist has only a neutral rating on each of Royal Caribbean and Norwegian Cruise Line -- and rates Carnival stock an out and out sell.

(Bloomberg) -- It’s been hard to watch, impossible to predict and a nightmare to trade. But has the S&P 500’s slide been an unqualified panic to date? By some measures no, and that might bode poorly for equities in the near term. Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightElon Musk Gets Defensive Over Twitter Meme as Harassment Report SurfacesApple Shows AR/VR Headset to Board in Sign of Progress on Key Project Stocks Avert Bear

Nio (NYSE: NIO) shares began trading on the main board of the Singapore stock exchange today prior to the opening of the U.S. markets. After initially popping 20% early, the new shares ended up closing in Singapore about 2.4% higher, according to Barron's.

Investors weren't overjoyed about a fresh debt offering announced by Carnival, and a bearish new note from an analyst didn't help, either. After market hours on Wednesday, Carnival announced that it is floating a private offering of $1 billion worth of senior unsecured notes. Carnival says it plans to use the net proceeds of the issue to make scheduled principal payments on debt during fiscal 2023 and for general corporate purposes.

In this article, we discuss 10 financial stocks that Warren Buffett is buying in 2022. If you want to see more financial stock picks of the billionaire, click Warren Buffett is Buying and Holding These 5 Financial Stocks in 2022. Warren Buffett follows the Benjamin Graham school of thought, picking value plays with prices that […]

Rising interest rates, supply chain constraints and Russia’s invasion of Ukraine are all issues currently plaguing the macro climate. The problem with all three, says Tony Dwyer, Canaccord Chief Market Strategist, is that for each problem there’s “no easy exit strategy.” The tough conditions are likely to persist, then. However, on the plus side, while these issues have sent most corners of the stock market into a tailspin, now investors are presented with stocks for which the term “oversold” re

Like many tech and fintech stocks this year, the Berkshire Hathaway-backed Brazilian digital bank Nu Holdings (NYSE: NU) has seen its stock price struggle and is down more than 61% this year. Nu is a major disruptor in the Latin American banking space, first offering a credit card with no annual fees and then building out a suite of banking products from there. Nu has amassed close to 60 million customers but in the past has gotten questions regarding its high valuation and path to sustainable profitability.

In this article, we discuss Michael Burry’s short position in Apple Inc. (NASDAQ:AAPL) and the 5 stocks he is selling in 2022. If you want to skip our analysis of Burry’s history, investment philosophy, and hedge fund performance, go directly to Michael Burry Is Selling These 3 Stocks in 2022. Michael Burry was born on […]